Aim Bulletin

MaxCyte enters licence agreement with Kamau Therapeutics

By Josh White

Date: Monday 16 Sep 2024

(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-stage firm specialising in stem cell gene correction therapies, on Monday.
The AIM-traded firm said the collaboration aimed to accelerate the development of cell therapies for genetic diseases, including sickle cell disease (SCD).

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page